numerous applications in the pharmaceutical industries, where the increasing impact of new therapeutics and "absorption, distribution, metabolism and excretion" (ADME) studies is leading to an increasing demand for the efficient synthesis of isotopically labeled compounds. [4] In this context, highly selective transition metal-catalyzed HIE reactions at aromatic CÀ H moieties of pharmaceuticals are still one of the key challenges, [5] because the catalyst needs to be compatible with a variety of functional groups that are commonly present in marketed pharmaceuticals. The most prominent homogeneous catalysts for the late-stage modification of drug candidates are Crabtree's iridium catalyst [6] and Kerr's iridium-carbene complex, [7] among other transition metal species. [8] Despite the increasing synthetic abilities of metal complexes towards CÀ H activation of organic molecules, [9] selective HIE of pharmaceuticals continuous to be extremely rare. A recent example that addresses this synthetic challenge by the Chirik group achieved the deuteration and tritiation of pharmaceutical drugs at aromatic CÀ H moieties with orthogonal site selectivity relative to Crabtree's iridium catalyst (Figure 1a ). [10] Furthermore MacMillan described the direct HIE of α-amino CÀ H bonds mediated by photoredox catalysis (Figure 1b ). [11] This method uses D 2 O/ T 2 O as a promising strategy to incorporate deuterium or tritium, due to cost efficiency and its user-friendly handling. [12] In sharp [ [13] Within our program on weak chelation assistance for CÀ H activation, [14] mechanistic studies had indicated the potential for a selective isotope incorporation into different structural motifs. Consequentially, we hypothesized that, instead of trapping the ruthenacycle with a carbon source, the use of D 2 O or T 2 O could facilitate the preparation of isotope labeled compounds. Thus, we herein present a robust and selective strategy for the ruthenium-catalyzed hydrogen isotope exchange by a weaklycoordinating carboxylic acids ( Figure 1c ). Our approach features inter alia (a) the use of a versatile ruthenium(II)-catalyst, (b) deuterated water as most user-friendly isotope source, (c) selective ortho-deuteration of bioactive compounds and (d) tritium-labeling of a marked pharmaceutical.
We commenced our studies by probing the envisioned HIE of p-anisic acid by different ruthenium sources with D 2 O. Notably, additive-free conditions provided poor results with the simple dichlororuthenium catalyst (entry 1). Instead, the use of well-defined ruthenium(II)biscarboxylate complexes afforded the desired HIE, with adamantyl carboxylate as ligand giving the best performance in terms of yield, with excellent deuterium-incorporation (entries 2 and 3 and Table S-1 in the Supporting Information). Next, we tested different deuterium sources, as it's known for palladium, that more acidic labeling reagents led to higher deuterium-incorporation. [15] Interestingly, methanol-d 4 gave a similar result (entry 4) and acetic acid-d 4 resulted in a reduced yield (entry 5). At a reduced reaction temperature the desired HIE did not occur in a satisfying yield (entry 6), while higher temperatures than 100°C showed no beneficial effect (entry 7). Next, we tested the effect of air and observed that the deuterium-incorporation was unaffected by the presence of air (entry 8). To improve the yield we switched to a solvent mixture in order to avoid high polar solvents and to use the labeling agent in reduced amounts. To our delight the use of 1,4-dioxane gave excellent deuterium-incorporation (Table 1, entry 9 and Table S-1 in the Supporting Information). Control experiments verified the essential nature of the ruthenium catalyst for the HIE process.
With the optimized reaction conditions in hand, we then examined the substrate scope of the ruthenium-catalyzed CÀ H hydrogen isotope exchange with D 2 O (Scheme 1). To this end, we first evaluated various benzoic acids 1. Electron-donating and electron-withdrawing substituents were well tolerated, yielding high labeled compounds [D] n -1. With substituents in the para position the deuterium-labeling is good (60-85 %) (1 a-c), whereas ortho-and meta-substituted benzoic acids showed excellent deuterium-incorporation (1 f-h, and 1 j-l) . The outstanding chemoselectivity of the ruthenium(II)-carboxylate catalyst was reflected by fully tolerating valuable functional groups, such as nitro (1 d, 1 i, 1 m), cyano (1 e, 1 n) , hydroxyl (1 o) and amino groups (1 p).
Furthermore, different (hetero)arenes were tested under the reaction conditions. To our delight they were obtained in a chemoselective manner, with selective and high deuterium incorporation in the ortho-position to the carboxyl group. Heterocyclic motifs, including indole (2), 1H-pyrazole (4) and oxazepine (5) , were well tolerated. Importantly, in case of 3 only a poor deuteration in the C2-position was observed, probably due to steric interactions.
The rate-determining CÀ H activation was confirmed by an experimental KIE value of k H /k D = 2.0 (Scheme 2a). Additionally, intermolecular competition experiments with differently sub- Communications stituted substrates 1 c and 1 q revealed, that the more electrondonating substrate reacted preferentially, providing strong support for a base-assisted internal electrophilic type substitution (BIES) regime (Scheme 2b). [16] On the basis of our mechanistic findings, we propose a plausible reaction pathway for the present HIE reaction (Scheme 3a). The reaction of 1 c with the ruthenium(II)-carboxylate complex (6) yields a ortho-metallated ruthenacycle via a BIES CÀ H-activation transition state (TS1). H/D exchange of the hydro carboxylato ligand with a deuterium source and further deutero-demetallation then yields [D] 1 -1 c. To gain additional insights into the HIE, we followed the kinetic profile of 1 c by inoperando 1 H-NMR spectroscopy (Scheme 3b). The synthetic utility was highlighted by the fast rate of the HIE, yielded > 78 % deuterium-incorporation after 5 h.
Given the excellent performance of highly functionalized (hetero)arenes, the envisioned labeling of challenging pharmaceuticals was targeted. We were pleased to find that the desired transformation could be achieved in sufficient yield and moderate to excellent deuterium-incorporation (Scheme 4).
The robustness of the CÀ H deuteration was highlighted by tolerating different structural motifs, like amide in repaglinide (7), benzimidazole in telmisartan (8), free sulfonamide or secondary amines in bumetanide (9) and α-amino-pyridines as well as diazo-motifs in sulfasalazine (10) . In addition to the generally high levels of deuterium incorporation observed for complex pharmaceuticals, we continued our studies with biologically active sulfonamides 11-14. To our delight the catalyst showed no solubility issues [17] and the performance was not inhibited by functional groups that often deactivate transition metal catalyst such as free amino (11) or hydroxyl (13) groups. Based on the high performance of the H/D exchange, we became interested in the ortho-selective tritium labeling of pharmaceuticals with T 2 O, to generate metabolically stable sites that are compatible to different functional groups. Thus, we tested the influence of different amounts of deuterium in the desired transformation. We were pleased to find that 6 equivalents of D 2 O yielded 80 % deuterium-incorporation (Table S-2 in the Supporting Information). In addition, we also performed the HIE of repaglinide (7) with freshly prepared D 2 O. [18] In this case, we observed a decreased deuterium-incorporation in the ortho-position (50 %), which was nevertheless a promising result towards the use of T 2 O. Under slightly modified reaction conditions, we performed the tritium labelling of repaglinide (7) . Thus, were able to introduce tritium in moderate specific activity in a single step (Scheme 5).
Communications
In conclusion, we have reported on a novel ruthenium(II)catalyzed strategy for the selective HIE of pharmaceutical drugs via late-stage diversification. Hence, carboxylate assistance enabled versatile CÀ H deuteration with excellent levels of isotope incorporation and functional group tolerance. In addition, we have demonstrated a step-economical access to selectively tritium labeled drugs, an essential tool for the development of new therapeutics and molecular understanding .  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 
